Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov-Dec;29(6):e70006.
doi: 10.1111/hel.70006.

Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Vivek Mishra  1 , Debabrata Dash  1 , Aditya K Panda  1   2 , Sushil Kumar Pathak  1   2
Affiliations
Meta-Analysis

Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis

Vivek Mishra et al. Helicobacter. 2024 Nov-Dec.

Erratum in

Abstract

Background: Helicobacter pylori infection is a major global health concern and has been associated with a number of gastrointestinal disorders. Probiotics, especially Lactobacillus spp., have been suggested to have beneficial effect in managing H. pylori infection. This meta-analysis of randomized control trials (RCTs) aimed to evaluate the effect of Lactobacillus spp. supplementation on H. pylori eradication rates and associated side effects when combined with standard therapy.

Materials and methods: Relevant studies were retrieved from PubMed, Scopus, Google Scholar and the Cochrane Library. Comprehensive Meta-Analysis (CMA) Software 4.0 was used for all the statistical analyses. TSA 0.9.5.10 Beta software was used for the trial sequential analysis (TSA). GRADEpro GDT was used to assess the certainty of evidence.

Results: An analysis of 26 selected studies showed that supplementing with Lactobacillus spp. significantly increased the rates of H. pylori eradication in per-protocol (PP) analysis (Overall risk ratio [RR] = 1.063, p = 0.000, 95% CI of -0.21 to 2.11; adults: RR = 1.050, p = 0.005, 95% CI = -0.55 to 2.03, children: RR = 1.223, p = 0.001, 95% CI = -13.35 to 4.55). In comparison to quadruple therapy, Lactobacillus spp. supplementation to triple therapy showed significant benefit (RR: 1.124; p = 0.000, 95% CI of -0.48 to 2.61). L. reuteri supplementation indicated better efficacy (RR: 1.049; p = 0.055, 95% CI of -0.56 to 3.26) than Lactobacillus GG (RR: 0.980; p = 0.595, 95% CI of -0.69 to 1.21). The 28-30 day (RR: 1.103; p = 0.003, 95% CI of -2.14 to 4.19) and 14-day supplementation periods (RR: 1.102; p = 0.003, 95% CI of -1.69 to 3.51) showed the most improvement. The analysis also revealed that Lactobacillus spp. significantly reduced gastrointestinal side effects: nausea/vomiting (RR: 0.566; p = 0.037, -3.11 to 1.45), diarrhea (RR: 0.324; p = 0.000, -5.46 to 0.48), and abdominal pain (RR: 0.438; p = 0.007, -5.65 to 4.22). The effect on bloating was non-significant (RR: 0.820; p = 0.498, -4.01 to 0.96). TSA graphs validated sufficient evidence for the conclusions.

Conclusion: Lactobacillus spp. significantly enhances H. pylori eradication rates and may reduce gastrointestinal side effects when used alongside standard therapy, offering a promising adjunctive treatment option. The evidence was supported by TSA and assessed using GRADEpro, indicating a high certainty of the findings.

Keywords: H. pylori; Lactobacillus spp.; eradication therapy; meta‐analysis; probiotics; randomized control trials.

PubMed Disclaimer

References

    1. M. A. Senchukova, “Helicobacter Pylori and Gastric Cancer Progression,” Current Microbiology 79, no. 12 (2022): 383.
    1. M. Amieva and R. M. Peek, Jr., “Pathobiology of Helicobacter pylori‐Induced Gastric Cancer,” Gastroenterology 150, no. 1 (2016): 64–78.
    1. P. Malfertheiner, F. Megraud, C. A. O'Morain, et al., “Management of Helicobacter pylori Infection‐The Maastricht V/Florence Consensus Report,” Gut 66, no. 1 (2017): 6–30.
    1. K. A. Fauzia and V. P. Tuan, “Rising Resistance: Antibiotic Choices for Helicobacter pylori Infection,” Lancet Gastroenterology & Hepatology 9, no. 1 (2024): 7–8.
    1. Q. Ye, X. Shao, R. Shen, D. Chen, and J. Shen, “Changes in the Human Gut Microbiota Composition Caused by Helicobacter pylori Eradication Therapy: A Systematic Review and Meta‐Analysis,” Helicobacter 25, no. 4 (2020): e12713.

MeSH terms

Substances